Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5580424 | 0.90 | KIF11 (0.48) | KIF11 | |
| SCHEMBL34261 | 0.78 | KIF11 (0.56) | KIF11 | |
| SCHEMBL20701939 | 0.77 | KIF11 (0.40) | KIF11GRIN2DGRIN1GRIN2AGRIN2B | |
| SCHEMBL29053902 | 0.76 | KIF11 (0.68) | KIF11 | |
| SCHEMBL29053899 | 0.76 | KIF11 (0.68) | KIF11 | |
| SCHEMBL3665671 | 0.74 | KIF11 (0.55) | KIF11 | |
| SCHEMBL1633684 | 0.73 | CYP1A2 (0.47) | KIF11GRIN2DGRIN1GRIN2AGRIN2B | |
| SCHEMBL6035957 | 0.72 | KIF11 (0.44) | KIF11 | |
| SCHEMBL9555492 | 0.72 | KIF11 (0.37) | KIF11GRIN2DGRIN1GRIN2AGRIN2B | |
| SCHEMBL1975054 | 0.72 | KIF11 (0.37) | KIF11GRIN2DGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458206-B2 | Targeted conjugates and particles and formulations thereof | TVA (ABC), LLC (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200206356-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2020-07-02 | — | — | US | disclosed |
| US-10624967-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| CN-110478495-A | Target conjugate and its particle and preparation | TARVEDA THERAPEUTICS INC | 2019-11-22 | — | — | CN | disclosed |
| CN-106573077-B | Targeted conjugates and particles and formulations thereof | 塔弗达治疗有限公司 | 2019-07-30 | — | — | CN | disclosed |
| US-10322191-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180000959-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2018-01-04 | — | — | US | disclosed |
| US-20170312245-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2017-11-02 | — | — | US | disclosed |
| US-9750818-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170151339-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2017-06-01 | — | — | US | disclosed |
| CN-1192153-A | aPL immunoreactive peptides and conjugates thereof and methods of treating aPL antibody-mediated diseases | JOLLA PHARMA (US) | 1998-09-02 | — | — | CN | disclosed |
| WO-1997046251-A9 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | — | 1998-06-04 | — | — | WO | disclosed |
| EP-0833648-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LA JOLLA PHARMACEUTICAL (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997046251-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1997-12-11 | — | — | WO | disclosed |
| EP-0800529-A1 | PEPTIDES AND SYNTHETIC CELL MEMBRANES | MERCK PATENT GmbH (DE) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996040197-A9 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | — | 1997-04-24 | — | — | WO | disclosed |
| WO-1996040197-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996018645-A1 | PEPTIDES AND SYNTHETIC CELL MEMBRANES | MERCK PATENT GMBH (DE) | 1996-06-20 | — | — | WO | disclosed |
| US-5238922-A | Anticancer agents | MERCK & CO., INC. (US) | 1993-08-24 | — | — | US | disclosed |
| EP-0535731-A2 | Inhibitors of farnesyl protein transferase | MERCK & CO. INC. (US) | 1993-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000959-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | KIF11 988/4885GRIN2D 3535/4885GRIN1 2518/4885 |
| US-20170151339-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | CD47, CD44, FURIN | KIF11 347/4885GRIN2D 4586/4885GRIN1 4177/4885 |
| US-10624967-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | KIF11 988/4885GRIN2D 3535/4885GRIN1 2518/4885 |
| US-20200206356-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | KIF11 988/4885GRIN2D 3535/4885GRIN1 2518/4885 |
| US-10322191-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | KIF11 988/4885GRIN2D 3535/4885GRIN1 2518/4885 |
| US-11458206-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | KIF11 988/4885GRIN2D 3535/4885GRIN1 2518/4885 |
| US-20170312245-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | KIF11 988/4885GRIN2D 3535/4885GRIN1 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.